Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

This was the stock's fourth consecutive day of losses.

Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer ...

EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.09 which represents a decrease of $-2.33 or -3.17% from the prior close of $73.42. The stock opened at $70.54 and touched a ...

Zacks Research raised their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on ...

Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $73.42 which represents a decrease of $-0.73 or -0.98% from the prior close of $74.15. The stock opened at $73.53 and touched a ...